---
title: "Analyst Sees Yutrepia’s Strong Commercial Trajectory and Liquidia Pipeline Supporting Buy Rating and Billion-Dollar Sales Outlook"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295699064.md"
description: "Needham analyst Serge Belanger maintains a Buy rating on Liquidia Technologies with an $110 price target, citing Yutrepia's strong commercial trajectory. Q2 2026 revenue beat consensus due to market share gains in PAH and PH-ILD treatments. Supported by improved launch metrics and a larger sales force, Yutrepia is projected to reach at least $1B in annual sales by 2027 and potentially $2.5B at peak. While patent litigation poses a risk, the favorable risk-reward profile supports the positive outlook."
datetime: "2026-08-12T18:45:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295699064.md)
  - [en](https://longbridge.com/en/news/295699064.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295699064.md)
generator: "portal-rs"
---

# Analyst Sees Yutrepia’s Strong Commercial Trajectory and Liquidia Pipeline Supporting Buy Rating and Billion-Dollar Sales Outlook

Serge Belanger, an analyst from Needham, maintained the Buy rating on Liquidia Technologies. The associated price target is $110.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Serge Belanger has given his Buy rating due to a combination of factors tied to Yutrepia’s strong commercial trajectory and Liquidia’s broader pipeline. Yutrepia delivered second-quarter 2026 revenue modestly ahead of consensus, driven by meaningful share gains as it increasingly becomes the standard treatment in PAH and PH-ILD, supported by new patient starts and conversions from competing inhaled, oral and parenteral therapies.

Belanger also highlights improved launch metrics and a larger sales organization as reinforcing confidence in sustained growth, underpinning expectations for Yutrepia to reach at least $1B in annual sales by 2027 and potentially $2.5B at peak in PAH/PH-ILD. He further views Yutrepia’s opportunity in adjacent lung indications and the L606 program as not fully reflected in the stock, while acknowledging ongoing patent litigation as a risk but not enough to offset the overall favorable risk-reward profile that supports a Buy recommendation.

### Related Stocks

- [LQDA.US](https://longbridge.com/en/quote/LQDA.US.md)

## Related News & Research

- [Liquidia launches Phase 3 Re-Spire trial of L606 inhaled treprostinil in PH-ILD](https://longbridge.com/en/news/297786781.md)
- [Will FDA Fast Track for YUTREPIA in Raynaud’s Phenomenon Reshape Liquidia’s (LQDA) Narrative](https://longbridge.com/en/news/298038188.md)
- [aTyr Pharma expects FDA response by mid-September on efzofitimod Phase 3 sarcoidosis protocol](https://longbridge.com/en/news/297696098.md)
- [Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying](https://longbridge.com/en/news/297940670.md)
- [Liquidia Corporation $LQDA Shares Sold by Pale Fire Capital SE](https://longbridge.com/en/news/297896782.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**